Unanswered questions regarding the management of sunitinib-induced hypothyroidism

被引：0
|
作者：
David Garfield
Aleck Hercbergs
Paul Davis
机构：
[1] D Garfield is a medical oncologist affiliated with the University of Colorado Health Sciences Center,
[2] A Hercbergs is a Radiation Oncologist at the Cleveland Clinic Foundation,undefined
[3] Cleveland,undefined
[4] OH,undefined
[5] P Davis is Senior Associate Dean for Clinical Research and Professor of Medicine at Albany Medical College,undefined
[6] Albany,undefined
[7] NY,undefined
[8] USA.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hypothyroidism seems to be a risk of sunitinib therapy for cancer. The authors of this Viewpoint review the evidence for the occurrence of hypothyroidism in this setting and discuss possible actions of thyroid hormone replacement in the cancer patient.
引用
收藏
页码：674 / 674
相关论文
共 50 条
  • [31] Sunitinib-Induced Acute Liver Failure
    Aqsa, Anum
    Droubi, Sami
    Amarnath, Shivantha
    Al-Moussawi, Hassan
    Abergel, Jeffrey
    CASE REPORTS IN GASTROENTEROLOGY, 2021, 15 (01) : 17 - 21
  • [32] Sunitinib-induced sudden hearing loss
    Dekeister, Kathleen
    Graillot, Emmanuelle
    Durbec, Mickael
    Scoazec, Jean-Yves
    Walter, Thomas
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 792 - 793
  • [33] Sunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report
    Manir, Kazi Sazzad
    Banerjee, Debanti
    Bhowmick, Rahul
    Roy, Chhaya
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S818 - S819
  • [34] Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Bozkurt, Oktay
    Karaca, Halit
    Hacibekiroglu, Ilhan
    Kaplan, Muhammed Ali
    Duzkopru, Yakup
    Uysal, Mukremin
    Berk, Veli
    Inanc, Mevlude
    Duran, Ayse Ocak
    Ozaslan, Ersin
    Ucar, Mahmut
    Ozkan, Metin
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (03) : 230 - 234
  • [35] Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
    Buda-Nowak, Anna
    Kucharz, Jakub
    Dumnicka, Paulina
    Kuzniewski, Marek
    Herman, Roman Maria
    Zygulska, Aneta L.
    Kusnierz-Cabala, Beata
    MEDICAL ONCOLOGY, 2017, 34 (04)
  • [36] Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
    Ozkan, Metin
    Bozkurt, Oktay
    Hacibekiroglu, Ilhan
    Kaplan, Muhammet Ali
    Duzkopru, Yakup
    Uysal, Mukremin
    Karaca, Halit
    Berk, Veli
    Inanc, Mevlude
    Duran, Ayse Ocak
    Ozaslan, Ersin
    Ucar, Mahmut
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
    Anna Buda-Nowak
    Jakub Kucharz
    Paulina Dumnicka
    Marek Kuzniewski
    Roman Maria Herman
    Aneta L. Zygulska
    Beata Kusnierz-Cabala
    Medical Oncology, 2017, 34
  • [38] Sunitinib-induced cardiac hypertrophy and the endothelin axis
    Sourdon, Joevin
    Address, Corresponding
    Facchin, Caterina
    Certain, Anais
    Viel, Thomas
    Robin, Blaise
    Lager, Franck
    Marchiol, Carmen
    Balvay, Daniel
    Yoganathan, Thulaciga
    Favier, Judith
    Tharaux, Pierre-Louis
    Dhaun, Neeraj
    Renault, Gilles
    Tavitian, Bertrand
    THERANOSTICS, 2021, 11 (08): : 3830 - 3838
  • [39] Sunitinib-induced hypertension: close monitoring required
    Reactions Weekly, 2008, 1184 (1) : 1 - 1
  • [40] A Rare Case of Sunitinib-Induced Exfoliative Esophagitis
    Gayam, Swapna
    Anumandla, Ashwini
    ACG CASE REPORTS JOURNAL, 2016, 3 (04)
12345